Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$0.10 and traded as low as C$0.10. Resverlogix shares last traded at C$0.11, with a volume of 15,310 shares.
Resverlogix Stock Performance
The stock has a market cap of C$31.61 million, a PE ratio of -3.67 and a beta of 0.78. The company has a quick ratio of 0.04, a current ratio of 0.13 and a debt-to-equity ratio of -10.95. The stock’s fifty day moving average price is C$0.10 and its 200 day moving average price is C$0.09.
Resverlogix (TSE:RVX – Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported C$0.00 earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that Resverlogix Corp. will post -0.22 EPS for the current year.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Further Reading
- Five stocks we like better than Resverlogix
- What is a Bond Market Holiday? How to Invest and Trade
- Meta Platforms May Ditch NVIDIA Chips—Here’s Why Investors Care
- Ride Out The Recession With These Dividend Kings
- SoFi Technologies: From Fintech Speculation to Profit Engine
- Trading Stocks: RSI and Why it’s Useful
- Gold to $5,000? What Bank of America and UBS Have to Say
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
